J&J/Actelion - falling asleep fast and deeply while staying fully awake on innovation * In a nutshell: The Commission found competitive concerns due to the combination of two development programmes for insomnia drugs, currently in Phase II of clinical trials. These pipeline drugs are based on a novel mechanism of action, orexin-antagonists, which has already shown potential for having less side effects and reduced risk of dependency compared to existing insomnia treatments. Due to the lack of competing pipeline programmes, the transaction brought about a risk for innovation competition, if, post-merger, J&J were to discontinue, reorient or delay one of the parties’ pipelines. J&J offered two complementary sets of tailor-made remedies to address those concerns. Overview
Share on
|
|
The EU Commission clears the acquisition of a pharmaceutical company by a global conglomerate subject to a commitment that clinical development of innovative insomnia drugs will not be adversely affected by the merger (Johnson & Johnson / Actelion)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
